<br>        Inclusion Criteria for Screening<br><br>          -  Age: 18 years of age or older at the time of signing the informed consent.<br><br>          -  Diagnosis: Subjects with a diagnosis of asthma as defined by the National Institutes<br>             of Health at least one year prior to Visit 0.<br><br>          -  Symptomatic: Subjects with inadequately controlled asthma (ACQ-6 score >=1.5) despite<br>             ICS/LABA maintenance therapy at Visit 1.<br><br>          -  Asthma Control: In the 1 year prior to Visit 1<br><br>               -  A documented healthcare contact for acute asthma symptoms or<br><br>               -  A documented temporary change in asthma therapy for acute asthma symptoms,<br>                  according to a pre-specified asthma action plan (or equivalent)<br><br>          -  Current Asthma Maintenance Therapy: Subjects are eligible if they have required daily<br>             ICS/LABA for at least 12 weeks prior to Visit 0 with no changes to maintenance asthma<br>             medications during the 6 weeks immediately prior to Visit 0 (including no changes to a<br>             stable total dose of ICS of >250 mcg/day fluticasone proprionate [FP, or equivalent]).<br><br>          -  Spirometry: A best pre-bronchodilator morning (ante meridian [AM]) FEV1 >=30% and <85%<br>             of the predicted normal value at Visit 1. Predicted values will be based upon the<br>             European Respiratory Society (ERS) Global Lung Function Initiative.<br><br>          -  Reversibility of Disease: airway reversibility defined as >=12% and >=200 milliliter<br>             (mL) increase in FEV1 between 20 and 60 minutes following 4 inhalations of<br>             albuterol/salbutamol aerosol at Visit 1.<br><br>          -  If the subject does not meet the above reversibility criteria at Visit 1 then the<br>             reversibility assessment may be repeated once within 7 days of Visit 1 if either<br>             criteria a) or b) are met: a) >=9% increase in FEV1 between 20 and 60 minutes<br>             following 4 inhalations of albuterol/salbutamol aerosol at Visit 1. b) Documented<br>             evidence of a reversibility assessment within 1 year prior to Visit 1 which<br>             demonstrated a post-bronchodilator increase in FEV1 of >=12% and >=200 mL.<br><br>        Should the subject successfully demonstrate airway reversibility (defined as >=12% and<br>        >=200 mL increase in FEV1 between 20 and 60 minutes following 4 inhalations of<br>        albuterol/salbutamol aerosol) at the second attempt then, provided that all other<br>        eligibility criteria assessed at Visit 1 are met, the subject may enter the 3-week run-in<br>        period.<br><br>          -  Short-Acting beta2 Agonists (SABAs): All subjects must be able to replace their<br>             current SABA inhaler with albuterol/salbutamol aerosol inhaler at Visit 1 as needed<br>             for the duration of the study. Subjects must be judged capable of withholding<br>             albuterol/salbutamol for at least 6 hours prior to study visits.<br><br>          -  Male or eligible Female, defined as having documentation of non-reproductive potential<br>             or reproductive potential as follows:<br><br>        A female subject is eligible to participate if she is not pregnant (as confirmed by a<br>        negative serum human chorionic gonadotrophin (hCG) test), not lactating, is not planning on<br>        becoming pregnant during the study and at least one of the following conditions applies:<br>        Non-reproductive potential defined as pre-menopausal females with documented tubal ligation<br>        or documented hysteroscopic tubal occlusion procedure with follow-up confirmation of<br>        bilateral tubal occlusion or hysterectomy or documented bilateral oophorectomy;<br>        Postmenopausal defined as 12 months of spontaneous amenorrhea with an appropriate clinical<br>        profile (e.g., age appropriate, >45 years, in the absence of hormone replacement therapy).<br>        In questionable cases for women <60 years of age, a blood sample with simultaneous follicle<br>        stimulating hormone and estradiol falling into the central laboratory's postmenopausal<br>        reference range is confirmatory. Females under 60 years of age, who are on hormone<br>        replacement therapy (HRT) and whose menopausal status is in doubt, are required to use a<br>        highly effective method to avoid pregnancy if they wish to continue their HRT during the<br>        study. Otherwise, they must discontinue HRT to allow confirmation of post-menopausal status<br>        prior to study enrolment. For most forms of HRT, at least 2 to 4 weeks will elapse between<br>        the cessation of therapy and the blood draw; this interval depends on the type and dosage<br>        of HRT. Following confirmation of their post-menopausal status, subjects can resume use of<br>        HRT during the study without use of a highly effective method to avoid pregnancy;<br>        Reproductive potential and agrees to follow one of the options listed in the Modified List<br>        of Highly Effective Methods for Avoiding Pregnancy in Females of Reproductive Potential<br>        (FRP) from the screening visit until after the last dose of study medication and completion<br>        of the follow-up visit. The Investigator is responsible for ensuring that subjects<br>        understand how to properly use these methods of contraception.<br><br>          -  Informed Consent: Able to give written informed consent prior to participation in the<br>             study, which will include the ability to comply with the requirements and restrictions<br>             listed in the consent form and in this protocol. Subjects must be able to read,<br>             comprehend, and write at a level sufficient to complete study related materials.<br><br>        Exclusion Criteria for Screening<br><br>          -  Pneumonia: Chest X-ray documented pneumonia in the 6 weeks prior to Visit 1.<br><br>          -  Asthma Exacerbation: Any asthma exacerbation requiring a change in maintenance asthma<br>             therapy in the 6 weeks prior to Visit 1. Note: Subjects requiring a temporary change<br>             in asthma therapy (e.g., oral corticosteroids or increased dose of ICS) to treat an<br>             exacerbation in the 6 weeks prior to Visit 1 are not explicitly excluded at Visit 1<br>             provided that, at the Investigator's discretion, the subject's condition is stable<br>             after they have resumed their pre-exacerbation maintenance asthma therapy (without<br>             modification) and they are considered appropriate for enrolment into this study of up<br>             to 12 month's duration.<br><br>          -  Chronic Obstructive Pulmonary Disease: Subjects with the diagnosis of chronic<br>             obstructive pulmonary disease, as per Global Initiative for Chronic Obstructive Lung<br>             Disease (GOLD) guidelines, including history of exposure to risk factors (i.e.,<br>             especially tobacco smoke, occupational dusts and chemicals, smoke from home cooking<br>             and heating fuels) and a post-albuterol/salbutamol FEV1/Forced Vital Capacity (FVC)<br>             ratio of <0.70 and a post-albuterol/salbutamol FEV1 of =<70% of predicted normal<br>             values and onset of disease >=40 years of age.<br><br>          -  Concurrent respiratory disorders: Subjects with current evidence of pneumonia, active<br>             tuberculosis, lung cancer, significant bronchiectasis, sarcoidosis, lung fibrosis,<br>             pulmonary hypertension, interstitial lung diseases or other active pulmonary diseases<br>             or abnormalities other than asthma.<br><br>          -  Risk Factors for Pne